Attention-Deficit/Hyperactivity Disorder (ADHD)

Comprehensive tutorial on ADHD including inattentive, hyperactive-impulsive, and combined presentations. Symptoms across the lifespan, DSM-5 diagnostic criteria, neurobiology, assessment, and evidence-based treatments including medication and behavioral interventions.

Mental Health 10 min read
This content is for informational purposes only. Always consult a healthcare professional.

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent patterns of inattention, hyperactivity, and impulsivity that interfere with functioning or development. Symptoms typically emerge in childhood and persist into adulthood for the majority of individuals.

Epidemiology

Metric Value
Worldwide prevalence (children) ~5-8%
Worldwide prevalence (adults) ~2.5-5%
Male:female ratio (children) 2-3:1
Male:female ratio (adults) ~1.5:1
Persistence into adulthood ~50-70% (some symptoms)
Full persistence into adulthood ~15-30%
Age of onset Symptoms before age 12

DSM-5 Diagnostic Criteria

ADHD is diagnosed based on a persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development.

Inattention Symptoms (6+ required for children; 5+ for age 17+)

No. Symptom Example
1 Fails to give close attention to details or makes careless mistakes Overlooks details in schoolwork, work tasks
2 Difficulty sustaining attention in tasks or play Difficulty remaining focused during lectures, conversations, long reading
3 Does not seem to listen when spoken to directly Mind seems elsewhere even without obvious distraction
4 Does not follow through on instructions and fails to finish tasks Starts tasks but quickly loses focus; easily sidetracked
5 Difficulty organizing tasks and activities Messy, disorganized work; poor time management; misses deadlines
6 Avoids or dislikes tasks requiring sustained mental effort Procrastinates on reports, forms, reviewing long papers
7 Loses things necessary for tasks or activities Loses keys, phone, wallet, glasses, school materials
8 Easily distracted by extraneous stimuli Attention drawn to irrelevant sounds, sights, thoughts
9 Forgetful in daily activities Forgets appointments, returns calls, pays bills, keeps obligations

Hyperactivity-Impulsivity Symptoms (6+ required for children; 5+ for age 17+)

No. Symptom Example
1 Fidgets with or taps hands or feet or squirms in seat Cannot keep hands still; needs to be moving
2 Leaves seat in situations when remaining seated is expected Gets up in meetings, classroom, dinner table
3 Runs about or climbs in inappropriate situations Restlessness (adults may feel very restless)
4 Unable to play or engage in leisure activities quietly Talks too loud; activities are noisy
5 On the go, acting as if driven by a motor Uncomfortable being still for extended time; driven
6 Talks excessively Interrupts; cannot stop talking
7 Blurts out answers before question is completed Finishes people’s sentences; cannot wait turn
8 Difficulty waiting turn Impatient in lines, traffic, conversations
9 Interrupts or intrudes on others Butts into conversations, games, activities; uses others’ things

Additional Criteria

Criterion Description
Age of onset Several inattentive or hyperactive-impulsive symptoms present before age 12
Pervasiveness Several symptoms present in two or more settings (home, school, work, with friends/family)
Impairment Clear evidence symptoms interfere with or reduce quality of social, academic, or occupational functioning
Exclusion Not better explained by another mental disorder (e.g., mood, anxiety, dissociative, personality, substance)

Presentation Specifiers

Presentation Predominant Symptoms
Combined presentation Both inattention and hyperactivity-impulsivity criteria met for past 6 months
Predominantly inattentive presentation Inattention criteria met but hyperactivity-impulsivity not met for past 6 months
Predominantly hyperactive-impulsive presentation Hyperactivity-impulsivity criteria met but inattention not met for past 6 months

Severity Specifiers

Level Description
Mild Few, if any, symptoms in excess of those required; minor or no impairment in functioning
Moderate Symptoms or functional impairment between mild and severe
Severe Many symptoms in excess of required; marked impairment in functioning

Symptoms Across the Lifespan

Childhood (Early Childhood through Elementary School)

Domain Presentation
Inattention Difficulty following instructions; loses materials; careless mistakes; does not seem to listen
Hyperactivity Runs/climbs excessively; cannot sit still; fidgets; talks excessively
Impulsivity Blurts out; interrupts; difficulty waiting turn; grabs things; acts without thinking
Academic Underperformance relative to ability; incomplete work; homework struggles
Social Difficulty making/keeping friends; bossy; intrudes; poor social timing
Emotional Low frustration tolerance; temper outbursts; emotional lability

Adolescence

Domain Presentation
Inattention More internal restlessness than overt hyperactivity; procrastination; poor planning
Hyperactivity Fidgeting; difficulty with sustained sedentary activities
Impulsivity Risky behavior (substance use, reckless driving, unprotected sex); verbal impulsivity
Academic Difficulty with complex assignments; disorganization; test anxiety; failure to meet deadlines
Social Peer problems; rejection sensitivity; difficulty reading social cues
Emotional Increased mood lability; self-esteem issues; frustration with school
Executive function Significant deficits in planning, prioritizing, time management

Adulthood

Domain Presentation
Inattention Difficulty with detail-oriented work; forgets appointments and commitments; easily overwhelmed
Hyperactivity Inner restlessness; difficulty relaxing; need to stay busy; fidgeting (may be more subtle)
Impulsivity Impulsive spending; interrupting; difficulty saving money; substance use; reckless driving
Occupational Job changes; underemployment; not meeting potential; difficulty with meetings and deadlines
Relationships Interpersonal conflict; forgetfulness perceived as uncaring; difficulty with household responsibilities
Time management Chronic lateness; poor time estimation; missed deadlines
Executive function Disorganization; poor planning; difficulty with task initiation and completion

Older Adults

Domain Presentation
Cognitive Worsening executive function with age-related cognitive decline; compensatory strategies may fail
Comorbidity Higher rates of depression, anxiety, substance use
Diagnostic challenges Symptoms overlap with normal aging, dementia, medical conditions

Gender Differences

Domain Males Females
Presentation More hyperactive-impulsive symptoms; diagnosed earlier More inattentive symptoms; diagnosed later
Diagnosis 2-3x more likely diagnosed in childhood Often missed in childhood; diagnosed in adulthood
Internalizing comorbidity Anxiety, depression Higher rates of anxiety, depression, BPD
Externalizing comorbidity ODD, CD, substance use ODD, CD (lower rates)
Coping Less likely to develop effective coping More likely to develop masking/coping strategies
Hormonal influences — Symptoms may worsen with hormonal fluctuations (menses, pregnancy, menopause)

Comorbid Conditions

Condition Prevalence in ADHD
Oppositional defiant disorder (ODD) ~40-60% (children)
Conduct disorder (CD) ~20-30% (children)
Anxiety disorders ~25-40%
Major depressive disorder ~15-30%
Bipolar disorder ~5-20%
Substance use disorders ~15-40% (adults)
Learning disorders ~25-40%
Autism spectrum disorder ~20-50% overlap
Tic disorders/Tourette ~7-20%
Sleep disorders ~25-75%
Borderline personality disorder ~15-30% (adults, especially women)

Neurobiology

Brain Structure and Connectivity

Region Changes in ADHD
Prefrontal cortex Reduced volume; delayed cortical maturation; reduced activation
Basal ganglia (striatum) Reduced volume (especially caudate); altered dopamine signaling
Cerebellum Reduced volume (especially vermis)
Anterior cingulate cortex Reduced activation during cognitive control
Parietal cortex Reduced activation in attentional networks
Corpus callosum Altered size (inconsistent findings)

Delayed cortical maturation:

  • Peak cortical thickness delayed by ~3 years in ADHD
  • Last to mature: Prefrontal cortex (executive control regions)
  • Maturation follows normal sequence but is delayed

Neurotransmitter Systems

System Role in ADHD Medication Target
Dopamine Attention, reward, motivation, executive function Stimulants increase dopamine
Norepinephrine Arousal, attention, working memory Atomoxetine, alpha-2 agonists increase norepinephrine

Genetics

Factor Finding
Heritability ~70-80%
First-degree relative risk 4-5x increased risk
Twin concordance (MZ) ~70-80%
Twin concordance (DZ) ~30-40%
Candidate genes DRD4, DRD5, DAT1, DBH, 5-HTT, SNAP25
GWAS findings Polygenic; multiple small-effect variants
Copy number variants Rare CNVs (e.g., 16p13.11 duplication) increase risk

Environmental Risk Factors

Factor Risk
Prenatal Maternal smoking, alcohol, stress, prematurity, low birth weight
Perinatal Birth complications, hypoxia, low Apgar scores
Early childhood Lead exposure, traumatic brain injury, early deprivation (institutional care)
Psychosocial Severe early adversity, neglect (correlational; confounding with genetics)

Assessment and Diagnosis

Diagnostic Process

Component Description
Clinical interview Developmental history, symptom review, functional impairment across settings
Rating scales Standardized questionnaires for patients, parents, teachers, partners
Collateral information Reports from family, teachers, significant others
Rule out mimics Screen for mood, anxiety, substance, sleep, learning, and medical disorders
Medical evaluation Rule out medical causes (thyroid, vision/hearing, sleep apnea, lead exposure)

Common rating scales:

  • Children: Conners Rating Scales, Vanderbilt ADHD Diagnostic Rating Scale, SNAP-IV
  • Adults: Adult ADHD Self-Report Scale (ASRS-v1.1), Conners Adult ADHD Rating Scales (CAARS), Brown Attention-Deficit Disorder Scales

Differential diagnosis:

Condition Distinguishing Features
Anxiety disorders Worry-driven; not present since early childhood
Mood disorders Episodic; not present since childhood; characterized by discrete episodes
Bipolar disorder Episodic; discrete manic/hypomanic episodes
Autism spectrum disorder Social communication deficits; restricted interests; sensory sensitivities
Learning disorders Specific academic skill deficits
Sleep disorders Daytime sleepiness mimics inattention
Substance use disorders Temporal relationship to substance use
Thyroid disorders Physical symptoms; lab findings
PTSD Trauma history; re-experiencing, avoidance, hyperarousal

Treatment

Pharmacotherapy

Stimulant medications (first-line):

Medication Duration Dose Forms Onset Key Points
Methylphenidate (MPH) 3-12 hours Immediate-release (IR), sustained-release (SR), extended-release (ER), osmotic-release (OROS) 30-60 min Available as patches, liquids, chewables
Dexmethylphenidate 4-12 hours IR, ER 30 min d-isomer of MPH; similar efficacy
Mixed amphetamine salts (MAS) 4-12 hours IR, ER 30-60 min Adderall, Adderall XR
Dextroamphetamine 4-12 hours IR, ER, prodrug 30-60 min Dexedrine; available as liquid
Lisdexamfetamine 10-14 hours Capsules, chewable 60-90 min Prodrug (converted in GI tract); extended duration
Methamphetamine (Desoxyn) 7-12 hours Tablets Third-line; limited use

Efficacy of stimulants:

  • Response rate: ~70-80%
  • Effect size: Large (0.8-1.2 for symptom reduction)
  • Number needed to treat (NNT): ~2-3

Non-stimulant medications (second-line):

Medication Duration Mechanism Key Points
Atomoxetine 24 hours (once daily) Norepinephrine reuptake inhibitor No abuse potential; takes 4-8 weeks for full effect; FDA-approved for children and adults
Guanfacine ER (Intuniv) 24 hours Alpha-2 adrenergic agonist For children/adolescents; useful for hyperactivity and impulsivity; also reduces tics
Clonidine ER (Kapvay) 12-24 hours Alpha-2 adrenergic agonist For children/adolescents; may cause sedation, hypotension
Bupropion 24 hours NDRI Off-label; useful with comorbid depression or smoking cessation
Tricyclic antidepressants (TCAs) 24 hours Norepinephrine reuptake Off-label; imipramine, nortriptyline; limited use

Medication monitoring:

Parameter Frequency
Height, weight Every 3-6 months (children); every 6-12 months (adults)
Heart rate, blood pressure At each visit; baseline before starting
Appetite, sleep At each titration and follow-up
Mood, anxiety Monitor for dysphoria, agitation, mood lability
Cardiovascular history EKG if personal/family cardiac history
Abuse/diversion risk Monitor prescription refill patterns

Behavioral and Psychological Interventions

Behavioral parent training (BPT):

  • For children with ADHD (ages 3-12)
  • Parents learn: consistent consequences, positive reinforcement, clear instructions, structured routines
  • Strong evidence for reducing disruptive behavior and improving parent-child relationship

Behavioral classroom management:

  • Teacher training in attention to positive behavior, daily report cards, structured routines
  • Token economy systems
  • Modified assignments, preferential seating

Cognitive-behavioral therapy (CBT) for adult ADHD:

  • Focus areas: Planning, organization, time management, procrastination
  • Cognitive restructuring (addressing negative beliefs, shame)
  • Skills training for emotion regulation, impulsivity control

Coaching and organizational skills training:

  • Concrete skill building: using planners, organizing space, breaking down tasks
  • Weekly check-ins, accountability structures
  • May be helpful adjunct to medication
Intervention Children Adolescents Adults
Medication First-line First-line First-line
Behavior therapy/parent training Strong Moderate —
Classroom management Strong Moderate —
CBT Limited Limited Strong
Organizational skills training Moderate Moderate Moderate
Social skills training Limited (may not generalize) Limited —
ADHD coaching — Moderate Moderate

Multi-Modal Treatment

The MTA study (Multimodal Treatment Study of ADHD) found:

  • Medication management alone: Superior to behavioral treatment alone
  • Combined treatment (medication + behavioral): Not significantly better than medication alone for core ADHD symptoms
  • Combined treatment: Superior to medication alone for other areas (parent-child relationships, reading achievement, social skills)

Lifestyle and Complementary Interventions

Intervention Evidence Recommendation
Exercise Moderate (improves executive function, reduces symptoms) Recommended adjunct
Sleep hygiene Essential (sleep problems exacerbate ADHD) Recommended
Nutrition/elimination diets Limited (some benefit in small subset) Not routinely recommended
Omega-3 fatty acids Small effect size May be added as supplement
Neurofeedback Mixed; some promising results Possibly helpful; more research needed
Cognitive training Limited; does not generalize Not recommended
Mindfulness meditation Moderate (adults); emerging (children) Recommended adjunct

Special Populations

ADHD and the Educational System

  • IDEA (Individuals with Disabilities Education Act): ADHD qualifies under “Other Health Impairment”
  • 504 Plan: Accommodations (extended time, preferential seating, reduced assignments)
  • IEP (Individualized Education Program): May include special education services
  • Classroom accommodations: Preferential seating, extended test time, reduced homework, breaks, organizational support

ADHD and Driving

  • ADHD associated with 2-4x increased risk of motor vehicle accidents
  • Treatment (especially stimulant medication) reduces crash risk by ~40-50%
  • Recommendations: Avoid distractions, take medication before driving, limit night driving

ADHD and Substance Use

  • ADHD increases risk of substance use disorders (SUD) by ~1.5-2x
  • Untreated ADHD is a risk factor for SUD; treatment may reduce SUD risk
  • Stimulant treatment does NOT increase SUD risk (longitudinal studies)
  • Extended-release formulations preferred (lower abuse potential)
  • Atomoxetine is a good option for ADHD + SUD (non-controlled, no abuse potential)

Prognosis

Outcome Percentage
Symptoms persist into adulthood ~50-70%
Full remission in adulthood ~30-40%
Partial remission (symptoms without impairment) ~20-30%
Occupational impairment Higher unemployment, underemployment
Academic outcomes Lower educational attainment
Relationship difficulties Higher divorce rates; interpersonal problems
Substance use Increased risk
Driving outcomes Increased accidents, violations
Overall quality of life Lower (but improves with treatment)

Positive prognosis factors:

  • Early diagnosis and treatment
  • Higher IQ
  • Supportive family environment
  • Absence of severe comorbidity
  • Good treatment adherence

References

  1. American Psychiatric Association. (2022). Diagnostic and Statistical Manual of Mental Disorders (5th ed., text rev.). Arlington, VA: APA.
  2. Faraone, S. V., et al. (2021). The World Federation of ADHD International Consensus Statement. Neuroscience & Biobehavioral Reviews, 128, 789-818.
  3. Barkley, R. A. (2015). Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment (4th ed.). Guilford Press.
  4. National Institute of Mental Health. (2023). Attention-Deficit/Hyperactivity Disorder. NIMH.
  5. Cortese, S., et al. (2018). Comparative efficacy and tolerability of medications for ADHD in children, adolescents, and adults. Lancet Psychiatry, 5(9), 727-738.
  6. MTA Cooperative Group. (1999). A 14-month randomized clinical trial of treatment strategies for ADHD. Archives of General Psychiatry, 56(12), 1073-1086.
  7. Shaw, P., et al. (2007). Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation. PNAS, 104(49), 19649-19654.